Overview

A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer

Status:
Completed

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to establish the safety profile of oral (by mouth) abiraterone acetate and oral prednisone following short-term administration after standardized low-fat or high-fat meals to patients with metastatic (spreading) castration-resistant prostate cancer (mCRPC).

Phase:

Phase 2

Details

Lead Sponsor:

Janssen-Ortho Inc., Canada

Treatments:

Abiraterone Acetate
Prednisone